ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 7646-7646 ◽  
Author(s):  
K. Lee ◽  
S. Han ◽  
H. Min ◽  
D. Oh ◽  
S. Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Excision Repair ◽  
Direct Sequencing ◽  
Small Cell ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
Ercc1 Expression

7646 Background: To investigate whether excision repair cross-complementation group 1 (ERCC1) expression, as determined immunohistochemically, and mutations of epidermal growth factor receptor (EGFR) are related to the prognosis of curatively resected non-small cell lung cancer (NSCLC), and whether these two markers are related. Methods: One-hundred and thirty-three consecutive patients with NSCLC who did not receive adjuvant chemotherapy after curative surgery were included in this study. Representative areas from formalin-fixed paraffin-embedded tumor samples were chosen for tissue microarray analysis. Immunohistochemistry was performed for ERCC1 and the median semiquantitative H-score was used as a cut-off. EGFR mutations (exons 18, 19, and 21) were analyzed by the direct sequencing of tumor samples. Results: ERCC1 expression was evaluable in 130 patients and ERCC1 was found to be positive in 80 patients (61.5%). Moreover, ERCC1 was expressed more frequently in smokers and in squamous cell carcinomas. Patients with positive ERCC1 expression survived longer (median overall survival 2,742 days for ERCC1-positive vs. 1,423 days for ERCC1-negative, P=.0463). EGFR mutations were found in 27 patients (20.3%) but they were not found to affect overall survival. Interestingly, EGFR mutations were more frequent in ERCC1-negative tumors (12.5% in ERCC1-positive vs. 30% in ERCC1-negative tumors, P=0.014). Conclusions: ERCC1 expression was identified as a prognostic marker of longer survival in resected NSCLCs. In addition, EGFR mutations were more frequently found in ERCC1-negative tumors, but were not found to affect survival in our patient group. No significant financial relationships to disclose.

ERCC1 expression and survival in small cell lung cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e19080-e19080
Author(s):  
M. Hennemann ◽  
M. H. Sostruznik ◽  
A. M. Gaiger ◽  
C. H. Barrios
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Median Survival ◽  
Cell Lung Cancer ◽  
Excision Repair ◽  
Small Cell ◽  
Positive Staining ◽  
Small Cell Lung ◽  
Ercc1 Expression

e19080 Background: The excision repair cross-complementation group 1 (ERCC1) protein expression has been suggested as both predictive or prognostic according to the administration or not of cisplatin-based chemotherapy in non-small cell lung cancer. It's role in small cell lung cancer (SCLC) is still uncertain. Methods: Forty four patients (pts) with diagnosis of SCLC were retrospectively analyzed. Paraffin blocks were reviewed to reconfirm a SCLC diagnosis and submitted to semi-quantitative immunohistochemical (ICH) method to detect the ERCC1 protein. The criteria for ERCC1 IHC evaluation was based on the percentage of cells with positive staining. Medical charts were reviewed and findings correlated to the IHC expression. All pts were treated with standard cisplatin-based chemotherapy and concomitant radiotherapy when appropriate according to stage. We report the correlation of ERCC1 expression with the overall survival of the population. Results: The group of pts had 59% (n=26) men with a median age of 60,8 years (±10). Staging revealed limited disease (LD) in 41% (n=18), extensive disease (ED) in 55% (n=24) and was not available from the chart review in 7% (n=3). The median survival time (MST) was 15.84 (±9.73) months (mo) in LD; 8.39 (±8.53) mo in ED. ERCC1 was positive in 50% (n=22) of the pts. From these, 54% (n=12) had ≥50% of the cells with positive staining. The overall median survival of this group was 10.8 (±8.6) mo. The 45% (n=10) of cases presenting with <50% of cells with positive staining had an overall survival of 13 (±10) mo. In the group with positive ERCC1 expression, 45%(n=10) had LD and median survival of 17.1 (±7.8) mo [≥50% staining (n=6): median survival 12.1 (±3.9) mo; <50% staining (n=4): median survival 24.4 (±6.1) mo]. The 11 pts with ERCC1 expression and ED had a median survival of 7.9 (±8.7) mo. [≥50% staining (n=6): median survival 9.4 (±12) mo; <50% staining (n=5): median survival 6.1 (±1.5) mo]. The group with no ERCC1 expression (n=22)] had an overall survival of 9.7 (±10.1) mo. Of these pts 7 had LD and a median survival of 14.03 (±12.4) mo, while 13 pts had ED and a median survival of 8.76 (±8.73) mo. Conclusions: In this group of SCLC pts ERCC1 expression by IHC does not seem to correlate with survival. No significant financial relationships to disclose.

ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer

Lung Cancer ◽  
2008 ◽  
Vol 60 (3) ◽  
pp. 401-407 ◽  
Author(s):  
Kyung-Hun Lee ◽  
Hye Sook Min ◽  
Sae-Won Han ◽  
Do-Youn Oh ◽  
Se-Hoon Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
Ercc1 Expression

scholarly journals Post-Progression Survival Is Strongly Associated with Overall Survival in Patients Exhibiting Postoperative Relapse of Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Medicina ◽  
2021 ◽  
Vol 57 (5) ◽  
pp. 508
Author(s):  
Hisao Imai ◽  
Ryoichi Onozato ◽  
Maiko Ginnan ◽  
Daijiro Kobayashi ◽  
Kyoichi Kaira ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Performance Status ◽  
Small Cell ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
Individual Patient Level ◽  
Egfr Mutated

Background and Objective: Patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitizing epidermal growth factor receptor (EGFR) mutations show a good response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). The subsequent treatments influence the evaluability of the efficacy of front-line therapy on overall survival (OS). Consequently, we evaluated the associations of relapse-free survival (RFS) and post-progression survival (PPS) with OS in patients who exhibited postoperative relapse of EGFR-mutated NSCLC. Materials and Methods: We analyzed the data of 35 patients with EGFR-mutated NSCLC who underwent complete resection between January 2007 and June 2019. The correlations of RFS and PPS with OS were evaluated at the individual patient level. Results: Linear regression and Spearman’s rank correlation analyses demonstrated that the PPS highly correlated with OS (r = 0.91, p < 0.05, R2 = 0.85), whereas the RFS weakly associated with OS (r = 0.36, p < 0.05, R2 = 0.25). Age and performance status at relapse were significantly associated with PPS. Conclusion: Overall, PPS was more strongly and significantly associated with OS than RFS. These results suggest that the OS of our cohort may be affected by treatments, besides postoperative relapse. However, larger-scale prospective studies are needed to confirm these results.

Sign in / Sign up

Export Citation Format

Share Document